New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 12, 2012
08:34 EDTIMMUImmunomedics' Epratuzumab in Lupus showed long-term efficacy and safety
Immunomedics announced that patients with moderate-to-severe lupus who had received continued cycles of epratuzumab therapy maintained improvements or further improved their lupus disease activity over a timeframe of approximately 4 years. Importantly, lower levels of median corticosteroid use were also maintained throughout the study. Results from this open-label, single-arm extension study of the Phase III ALLEVIATE trials were reported by clinical investigators at the 2012 American College of Rheumatology Annual Scientific Meeting in Washington DC. Immunomedics has licensed the rights to the development and commercialization of epratuzumab to UCB in all autoimmune diseases.
News For IMMU From The Last 14 Days
Check below for free stories on IMMU the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 8, 2014
08:36 EDTIMMUImmunomedics reports SN-38 results demonstrate high therapeutic index
Subscribe for More Information
April 7, 2014
11:04 EDTIMMUImmunomedics announces multiple partial responses with IMMU-132
Subscribe for More Information
11:04 EDTIMMUImmunomedics reports results from three IMMU-130 phase I trials
Immunomedics reported the results from 3 Phase I trials with IMMU-130, the company's investigational anti-CEACAM5 antibody conjugated to the irinotecan-metabolite, SN-38. The antibody-drug conjugate was therapeutically active in all 3 trials, but a more frequent dosing schedule, with administrations of IMMU-130 once or twice-weekly for 2 weeks followed by a week off, was more active in patients with metastatic colorectal cancer than when administered every other week. Results from these Phase I studies were presented at the 2014 Annual Meeting of the American Association for Cancer Research in San Diego, CA, by a group of clinical investigators. In all three trials, measurement of SN-38 concentrations in the serum found much higher levels that were sustained longer than is typically found with irinotecan therapy, the parental drug of SN-38. However, most of the SN-38 remains bound to the antibody, keeping it in an inactive form to normal tissues while in circulation, which reduces toxicity, yet allowing for higher concentrations of activated SN-38 to be delivered to the tumor where it is released from the pH- sensitive linker. Neutropenia and manageable diarrhea were the main side effects. "These results suggest that IMMU-130 may have a high therapeutic index and can be administered in repeated cycles in advanced mCRC patients," commented CEO Cynthia Sullivan.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use